DLX4 and breast cancer: However, significant differences were observed between the groups with low and high DLX7 expression in the distribution of clinical stages (P = 0.008, Table 1), with low DLX7 expression appearing with the highest frequency in the blastic crisis (BC) stage [88.9% (8/9)], lower frequency in the accelerated phase (AP) stage [83.3% (5/6)], and the lowest frequency in the chronic phase (CP) stage [43.3% (26/60)].